Applications published 5 August 2009

Modulation of amyloid-beta production
Satori Pharmaceuticals 2083621*

Omega-3 fatty acids for reduction of LP-PLA2 levels
Reliant Pharmaceuticals 2083622*

Substituted imidazoles as bombesin receptor subtype-3 modulators
Merck 2083623*

2-hydroxy-2-phenyl/thiophenyl propionamides as androgen receptor modulators
Merck 2083624*

Bicyclic heteroaromatic compounds
Glaxo Group 2083625*

Crystal modification of fipronil
BASF 2083626*

Crystal modification of fipronil
BASF 2083627*

Methods and devices to test diffusion rates of ocular drug delivery systems
Johnson & Johnson Vision Care 2083793*

• Semi-solid controlled release compsn
Hexal Gentech Forschungs 2083795*

• Enzyme inhibition using nanoparticles
McNeil-PPC 2083796*

• Stable liquid compsns for treating somatitis comprising epidermal growth factor
Deawoong 2083797*

• Pharmaceutical compsns and nasal spray incorporating anhydrous mometasone furoate
Cipla 2083798*

• Micellar nanoparticles of chemical substances
Solvay Pharmaceuticals 2083799*

• Device and method for patient activated bolus administration
MFS Medical Flow Systems 2083800*

• Divisible osmotic dosage forms and methods of use
Accu-Break Technologies 2083801*

• Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof
Reliant Pharmaceuticals 2083802*

• Formulations of active principles incorporated in SNLS suitable for transdermal administration
Nanovector 2083803*

• Compounds and methods for the modulation of toll-like receptor function
Provost, Fellows & Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin 2083804*

• Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders
DSM 2083805*

• Use of an anti-cancer compound
Universiti Putra Malaysia 2083806*

• Use of a combination of hypothermia inducing drugs
Meurokey 2083807*

• Use of buprenorphine or N-alkylated derivatives thereof for wound healing
Serentis 2083808*

• Dietary or pharmaceutical compsns containing tricyclic diterpenes and derivatives thereof for the treatment of depression
DSM  2083809*

• Compsns comprising carnosic acid 12-methylether
DSM 2083810*

• Methods of treating mental retardation, Down's syndrome, fragile X syndrome and autism
Seaside Therapeutics 2083811*

• Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
Rijksuniversiteit Groningen 2083812*

• Nutrient sensor
Baylor Research Institute 2083813*

• DMAE as sole agent for the treatment of mild cognitive impairment
Pierre Fabre Medicament 2083814*

• Statin and omega-3 fatty acids for reduction of APO-B levels
Reliant Pharmaceuticals 2083815*

• Heterocyclic amide compounds useful as kinase inhibitors
Bristol-Myers Squibb 2083816*

• Method of restoring the incretin effect
CPD 2083817*

• Melatonin derivatives and their use as antioxidants
University of Sunderland 2083818*

• PDE10 inhibitors and related compsns and methods
Omeros Corp 2083819*

• Pharmaceutical compsns comprising intra- and extra-granular fractions
Pharmascience 2083820*

• Novel 4-amino-pyridine derivatives and their use as potassium channel modulators
NeuroSearch 2083821*

• Substituted imidazoles as bombesin receptor subtype-3 modulators
Merck 2083822*

• Alcohol-free formulation of argatroban
Scidose 2083823*

• Methods for treating inflammatory conditions
Melior Discovery 2083824*

• Compsns for the treatment of hepatitis C and methods for using compsns for the treatment of hepatitis C
Addiction Research Institute 2083825*

• Methods for treating inflammatory conditions
Melior Discovery 2083826*

• Use of estradiol valerate or 17-estradiol in combination with dienogest for oral therapy for maintaining and/or increasing the female libido
Bayer Schering Pharma 2083827*

• A standardised extract and its use in the manufacture of a medicament
Botanic Century (Beijing) 2083828*

• Use of phosphoenolpyruvate derivatives for treating nextrosis of cardiac muscle tissue
Cardiosolutions 2083829*

• Improved methods of using phosphoantigen for the treatment of cancer
Innate Pharma 2083830*

• Method of treatment using fatty acid synthesis inhibitors
Merck 2083831*

• Novel 1,4-benzothiepin-1,1-dioxide derivatives with improved properties, method for producing the same, drugs containing said compounds and use thereof
Sanofi-Aventis Deutschland 2083832*

• Pharmaceutical anti-infective compsn for inhalation
Laboratoires SMB  2083833*

• Macrocyclic lactone compounds and methods for their use
Elixir Medical 2083834*

• Wound dressing compsns containing non-viable cell lysate
Systagenix Wound Management 2083835*

• Nutritional supplement
Wittenbaker, Neville 2083836*

• Therapeutic use of at least one botulic neurotoxin in the treatment of pain induced by at least one antineoplastic agent
Ipsen Pharma 2083837*

• Medicinal herbal extract having anti-obesity effect
Newgex 2083838*

• Antiviral astragalus extract
Phynova 2083839*

• Improved treatment for benign prostatic hyperplasia
Summa Development 2083840*

• Treatment for age-related macular degeneration and other diseases of the eye
Celldex Therapeutics 2083841*

• Analogues of ghrelin substituted at the N-terminal
Ipsen Pharma 2083842*

• Multifunctional carriers for the delivery of nucleic acids and methods of use thereof
University of Utah Research Foundation 2083843*

• HCV NS3 protease inhibitors
Merck 2083844*

• Ablative immunotherapy
Immunative Therapies 2083845*

• N-terminal FGF variants having increased receptor selectivity and uses thereof
Hepacore 2083846*

• Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies
Sigma-Tau Industrie Farmaceutiche Riunite 2083847*

• Method of treatment and prophylaxis
Melbourne Health 2083848*

• Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
Allergan 2083849*

• Methods and compsns for stabilising prostate specific antigen
Bio-Rad 2083850*

• (Base) modified RNA for increasing the expression of a protein
Curevac 2083851*

• Tumour immunity
Dana-Farber Cancer Institute 2083852*

• Shigella Ipad protein and its use as a vaccine against shigella infection
Institut Pasteur 2083853*

• Method for stimulating dendritic cells and cell product thus obtained for the autologous immunotherapy of solid human tumours
Fondazione I.R.C.C.S. IstitutoNeurologico ‘Carlo Besta" 2083854*

• Use of measles virus nucleoprotein for treating atherosclerosis
INSERM (Institut National de la Sante et de la Recherche Medicale) 2083855*

• Peptides for desensibilisation against allergens
Circassia 2083856*

• Methods for treating mica-related disorders
Dana-Farber Cancer Research 2083857*

• Humin immune therapies using a CD27 agonist alone or in combination with other immune modulators
University of Southampton 2083858*

• Antagonists of PCSK9
Merck 2083859*